explore -WSS

explore

author：entertainment 2025-09-29 22:50:35 - browse：1

Multiple syringes in a vial -- Pharma coverage from STAT — Adobe

Roughly two million Americans are expected to receive a cancer diagnosis this year. Some members of this already vulnerable group will wind up facing what physician Andrew Schuman recently called “a tragedy happening in slow motion” — an ongoing, nationwide shortage of critical oncology drugs that routinely save or extend the lives of children and adults.

Speaking at a March 22 Senate hearing on drug shortages, Schuman, a head and neck surgeon at the U.S. Department of Veterans Affairs, described the agonizing decisions that doctors must make when critical medicines are in short supply. “Should our limited vials go to an older woman who was just diagnosed with lung cancer? To a young man who had already been successfully taking it for his testicular cancer? Or a baby with neuroblastoma?” he asked. “As a doctor who has devoted my life to fighting cancer, it is hard to express how horrible it is to face this kind of tragedy.”

The dilemmas caused by cancer drug shortages are unfortunately nothing new. In the past decade alone, eight of the 10 drugs most commonly used to treat acute lymphoblastic leukemia, the most common kind of childhood cancer type of leukemia, have been temporarily unavailable. The problem has been getting worse: Nationwide shortages of critical drugs increased nearly 30% in 2022, soaring to their highest level in nearly five years, according to a report released by the Senate Homeland Security and Governmental Affairs Committee for the hearing. Oncology drugs currently in short supply include methotrexate, which treats breast and soft tissue cancers; cisplatin, which treats testicular, ovarian, bladder, head and neck, lung, and cervical cancers; fluorouracil, which treats skin cancer; Pluvicto, for prostate cancer; and the injectable bacillus Calmette-Guérin, for bladder cancer.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Secretariat’s lessons for human medicine

WSS

He's a Nobel laureate. Critics say he was misleading on Covid

Hospitals are piloting generative AI tools as regulators play catch

Measles policy set amid Florida outbreak alarms vaccine proponents

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

Alabama hospital puts IVF treatments on hold

Wikipedia

explore

hotspot

Trump demands the U.S. pay no more for drugs than other countries … again

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

Continuity nursing helped my family in our darkest PICU moments

FDA warns medical device makers about rise in fabricated data

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Measles policy set amid Florida outbreak alarms vaccine proponents

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

Heart attack and stroke risk calculators need revising

The Harvard botanist who searched for psychedelics in the Amazon

explore

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

Reporting on presidential health from Reagan to Trump and Biden

NIH study of ME/CFS points to clear biological hallmarks

New documents shed light on MD Anderson Cancer Institute feud

A new drug could help frostbite victims avoid its ravages

Elevance, SCAN deals highlight health insurer acquisition scrutiny

entertainment

Wikipedia

knowledge

hotspot